1. 1004OFinal overall survival results of frontline bortezomib plus rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) vs R-CHOP in transplantation-ineligible patients (pts) with newly diagnosed mantle-cell lymphoma (MCL): A randomized, open-label, phase III (LYM-3002) study. (23rd October 2018) Authors: Cavalli, F; Jin, J; Pylypenko, H; Verhoef, G; Siritanaratkul, N; Drach, J; Raderer, M; Mayer, J; Pereira, J; Tumyan, G; Okamoto, R; Nakahara, S; Hu, P; Appiani, C; Nemat, S; Robak, T Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Distribution and clinical significance of blood dendritic cells in children with juvenile idiopathic arthritis. Issue 6 (26th October 2007) Authors: Smolewska, E; Stańczyk, J; Brózik, H; Biernacka-Zielińska, M; Cebula, B; Robak, T; Smolewski, P Journal: Annals of the rheumatic diseases Issue: Volume 67:Issue 6(2008) Page Start: 762 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. (9th February 2018) Authors: Jurczak, W; Zinzani, P L; Gaidano, G; Goy, A; Provencio, M; Nagy, Z; Robak, T; Maddocks, K; Buske, C; Ambarkhane, S; Winderlich, M; Dirnberger-Hertweck, M; Korolkiewicz, R; Blum, K A Journal: Annals of oncology Issue: Volume 29:Number 5(2018) Page Start: 1266 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗